BLRX BioLine RxWatchlist
About BioLine Rx Company
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.
BioLine Rx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/20/2023 1204.35% HC Wainwright & Co. → $21 Reiterates Buy → Buy 09/15/2023 1204.35% HC Wainwright & Co.
Bioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growth